185 related articles for article (PubMed ID: 20569710)
1. A randomized controlled trial of low-dose hormone therapy on myocardial ischemia in postmenopausal women with no obstructive coronary artery disease: results from the National Institutes of Health/National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation (WISE).
Merz CN; Olson MB; McClure C; Yang YC; Symons J; Sopko G; Kelsey SF; Handberg E; Johnson BD; Cooper-DeHoff RM; Sharaf B; Rogers WJ; Pepine CJ
Am Heart J; 2010 Jun; 159(6):987.e1-7. PubMed ID: 20569710
[TBL] [Abstract][Full Text] [Related]
2. Effects of low-dose norethindrone acetate plus ethinyl estradiol (0.5 mg/2.5 microg) in women with postmenopausal symptoms: updated analysis of three randomized, controlled trials.
Rowan JP; Simon JA; Speroff L; Ellman H
Clin Ther; 2006 Jun; 28(6):921-32. PubMed ID: 16860174
[TBL] [Abstract][Full Text] [Related]
3. The effect of varying low-dose combinations of norethindrone acetate and ethinyl estradiol (femhrt) on the frequency and intensity of vasomotor symptoms.
Speroff L; Symons J; Kempfert N; Rowan J;
Menopause; 2000; 7(6):383-90. PubMed ID: 11127760
[TBL] [Abstract][Full Text] [Related]
4. Combined continuous ethinyl estradiol/norethindrone acetate does not improve forearm blood flow in postmenopausal women at risk for cardiovascular events: a pilot study.
Duvernoy CS; Rose PA; Kim HM; Kehrer C; Brook RD
J Womens Health (Larchmt); 2007 Sep; 16(7):963-70. PubMed ID: 17903073
[TBL] [Abstract][Full Text] [Related]
5. Does hormone therapy improve age-related skin changes in postmenopausal women? A randomized, double-blind, double-dummy, placebo-controlled multicenter study assessing the effects of norethindrone acetate and ethinyl estradiol in the improvement of mild to moderate age-related skin changes in postmenopausal women.
Phillips TJ; Symons J; Menon S;
J Am Acad Dermatol; 2008 Sep; 59(3):397-404.e3. PubMed ID: 18625536
[TBL] [Abstract][Full Text] [Related]
6. Reduced vaginal bleeding in postmenopausal women who receive combined norethindrone acetate and low-dose ethinyl estradiol therapy versus combined conjugated equine estrogens and medroxyprogesterone acetate therapy.
Simon JA; Liu JH; Speroff L; Shumel BS; Symons JP
Am J Obstet Gynecol; 2003 Jan; 188(1):92-9. PubMed ID: 12548201
[TBL] [Abstract][Full Text] [Related]
7. Vaginal bleeding in postmenopausal women taking low-dose norethindrone acetate and ethinyl estradiol combinations. The FemHRT Study Investigators.
Symons J; Kempfert N; Speroff L
Obstet Gynecol; 2000 Sep; 96(3):366-72. PubMed ID: 10960627
[TBL] [Abstract][Full Text] [Related]
8. Differing effects of low-dose estrogen-progestin therapy and pravastatin in postmenopausal hypercholesterolemic women.
Davis SR; Goldstat R; Newman A; Berry K; Burger HG; Meredith I; Koch K
Climacteric; 2002 Dec; 5(4):341-50. PubMed ID: 12626213
[TBL] [Abstract][Full Text] [Related]
9. Health related quality of life after combined hormone replacement therapy: randomised controlled trial.
Welton AJ; Vickers MR; Kim J; Ford D; Lawton BA; MacLennan AH; Meredith SK; Martin J; Meade TW;
BMJ; 2008 Aug; 337():a1190. PubMed ID: 18719013
[TBL] [Abstract][Full Text] [Related]
10. Escitalopram versus ethinyl estradiol and norethindrone acetate for symptomatic peri- and postmenopausal women: impact on depression, vasomotor symptoms, sleep, and quality of life.
Soares CN; Arsenio H; Joffe H; Bankier B; Cassano P; Petrillo LF; Cohen LS
Menopause; 2006; 13(5):780-6. PubMed ID: 16894334
[TBL] [Abstract][Full Text] [Related]
11. The effects of compounded bioidentical transdermal hormone therapy on hemostatic, inflammatory, immune factors; cardiovascular biomarkers; quality-of-life measures; and health outcomes in perimenopausal and postmenopausal women.
Stephenson K; Neuenschwander PF; Kurdowska AK
Int J Pharm Compd; 2013; 17(1):74-85. PubMed ID: 23627249
[TBL] [Abstract][Full Text] [Related]
12. A multicenter, open-label study to evaluate satisfaction and menopausal quality of life in women using transdermal estradiol/norethindrone acetate therapy for the management of menopausal signs and symptoms.
Adler G; Young D; Galant R; Quinn L; Witchger MS; Maki KC
Gynecol Obstet Invest; 2005; 59(4):212-9. PubMed ID: 15753617
[TBL] [Abstract][Full Text] [Related]
13. Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women's Health Initiative.
Barnabei VM; Cochrane BB; Aragaki AK; Nygaard I; Williams RS; McGovern PG; Young RL; Wells EC; O'Sullivan MJ; Chen B; Schenken R; Johnson SR;
Obstet Gynecol; 2005 May; 105(5 Pt 1):1063-73. PubMed ID: 15863546
[TBL] [Abstract][Full Text] [Related]
14. Effects of Oral vs Transdermal Estrogen Therapy on Sexual Function in Early Postmenopause: Ancillary Study of the Kronos Early Estrogen Prevention Study (KEEPS).
Taylor HS; Tal A; Pal L; Li F; Black DM; Brinton EA; Budoff MJ; Cedars MI; Du W; Hodis HN; Lobo RA; Manson JE; Merriam GR; Miller VM; Naftolin F; Neal-Perry G; Santoro NF; Harman SM
JAMA Intern Med; 2017 Oct; 177(10):1471-1479. PubMed ID: 28846767
[TBL] [Abstract][Full Text] [Related]
15. Validation of the Women's Health Initiative Insomnia Rating Scale in a multicenter controlled clinical trial.
Levine DW; Dailey ME; Rockhill B; Tipping D; Naughton MJ; Shumaker SA
Psychosom Med; 2005; 67(1):98-104. PubMed ID: 15673630
[TBL] [Abstract][Full Text] [Related]
16. Anti-ischemic action of estrogen-progestogen continuous combined hormone replacement therapy in postmenopausal women with established angina pectoris: a randomized, placebo-controlled, double-blind, parallel-group trial.
Sanderson JE; Haines CJ; Yeung L; Yip GW; Tang K; Yim SF; Jorgensen LN; Woo J
J Cardiovasc Pharmacol; 2001 Sep; 38(3):372-83. PubMed ID: 11486242
[TBL] [Abstract][Full Text] [Related]
17. Ranolazine improves angina in women with evidence of myocardial ischemia but no obstructive coronary artery disease.
Mehta PK; Goykhman P; Thomson LE; Shufelt C; Wei J; Yang Y; Gill E; Minissian M; Shaw LJ; Slomka PJ; Slivka M; Berman DS; Bairey Merz CN
JACC Cardiovasc Imaging; 2011 May; 4(5):514-22. PubMed ID: 21565740
[TBL] [Abstract][Full Text] [Related]
18. Contrasting effects of two hormone replacement therapies on the cardiovascular and mammary gland outcomes in surgically postmenopausal monkeys.
Suparto IH; Williams JK; Cline JM; Anthony MS; Fox JL
Am J Obstet Gynecol; 2003 May; 188(5):1132-40. PubMed ID: 12748457
[TBL] [Abstract][Full Text] [Related]
19. A randomized trial of three oral contraceptives: comparison of bleeding patterns by contraceptive types and steroid levels.
Saleh WA; Burkman RT; Zacur HA; Kimball AW; Kwiterovich P; Bell WK
Am J Obstet Gynecol; 1993 Jun; 168(6 Pt 1):1740-5; discussion 1745-7. PubMed ID: 8317516
[TBL] [Abstract][Full Text] [Related]
20. Coronary microvascular reactivity to adenosine predicts adverse outcome in women evaluated for suspected ischemia results from the National Heart, Lung and Blood Institute WISE (Women's Ischemia Syndrome Evaluation) study.
Pepine CJ; Anderson RD; Sharaf BL; Reis SE; Smith KM; Handberg EM; Johnson BD; Sopko G; Bairey Merz CN
J Am Coll Cardiol; 2010 Jun; 55(25):2825-32. PubMed ID: 20579539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
